Drugs / Nivatrotamab
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT04750239 | Aug 2021 → Apr 2022 | small cell lung carcinoma | Y-mAbs Therapeutics | Terminated | No outcome recorded Stop: Business |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2020-10-07 | Y-mAbs Therapeutics | Regulatory Y-mAbs’ Nivatrotamab for the Treatment of Patients with Neuroblastoma Granted Orphan Drug Designation and Rare Pediatric Disease Designation by FDA ymabs.com ↗
today announced that the FDA has granted Orphan Drug Designation (“ODD”) and Rare Pediatric Disease Designation (“RPDD”) for its leading bispecific antibody program nivatrotamab for the treatment of neuroblastoma. |
All press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2020-10-07 | Y-mAbs Therapeutics | Y-mAbs’ Nivatrotamab for the Treatment of Patients with Neuroblastoma Granted Orphan Drug Designation and Rare Pediatric Disease Designation by FDA ymabs.com ↗ |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Nivatrotamab | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04750239 ↗ |
| Known as | HU3F8-BSAB | ChEMBL registry synonym — accepted as the source's own label CHEMBL4650409 ↗ |
| Modality | Monoclonal antibody | “Anti GD2×CD3 monoclonal bi-specific antibody” NCT04750239 ↗ |
| Route | Subcutaneous | “Subcutaneous administration of nivatrotamab up to 13 cycles” NCT04750239 ↗ |